The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending the approval of MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C virus (HCV) infection in adults and children aged 3 and older. This oral antiviral treatment, already approved for chronic HCV, showed a 96% cure rate in a Phase 3 study. Approval would allow earlier treatment of acute HCV, which is often asymptomatic, helping reduce transmission and liver complications. The final decision by the European Commission is expected in Q3 2026, potentially expanding MAVIRET's use to both acute and chronic HCV in the EU.
Replacing a $65,000 annual salary with dividends requires a portfolio yield strategy. At a conservative 3% yield, you'd need about $2.17 million, but at an aggressive 10% yield, $650,000 suffices. Conservative stocks like Coca-Cola offer stability bu...
AbbVie presented new data at the 2026 ASCO Annual Meeting showcasing its oncology pipeline targeting solid tumors and blood cancers. Key findings include promising results from antibody-drug conjugates (ADCs) and T-cell engagers in cancers like metas...
Boey® (trenibotulinumtoxinE), developed by Allergan Aesthetics, received a positive opinion from the European Medicines Agency's CHMP for approval in 30 EU and EEA countries to temporarily improve moderate to severe glabellar lines in adults. Support...
More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to im...
The iShares U.S. Pharmaceuticals ETF (IHE) has gained 38% over the past year despite threats from U.S. drug pricing policies like the 'most favored nation' order. The ETF benefits from dividends and strong drug pipelines, especially from major holdin...
